Search:

Search for text in:

separate each search
term with a space

Multiple terms:

Additional Search Filters:

clear all | select all

Conference Years:

clear all | select all

Days Within Meeting:

clear all | select all

Conferences:

Availability:

clear all | select all

Participation Type:

clear all | select all

Topic Tracks*:

clear all | select all

Organ Site Tracks*:

Showing session: reset

Phase I Studies of Immune-Based Therapies and a Novel RNAi Agent

  • Sort by:
  • Browse by:
<< first | < prev page: of 1 records per page: next > | last >>
pages: 1 presentations: 1 to 7 of 7
Phase I Studies of Immune-Based Therapies and a Novel RNAi Agent
A phase I study of MPDL3280A, an engineered PD-L1 antibody in patients with locally advanced or metastatic tumors
Michael S Gordon
Premiere Oncology of Arizona, Scottsdale, AZ, United States
from AACR Annual Meeting 2013 on April 9, 2013 3:00 PM-5:00 PM
Phase I Studies of Immune-Based Therapies and a Novel RNAi Agent
Discussant
Antoni Ribas
UCLA Medical Ctr., Los Angeles, CA, United States
from AACR Annual Meeting 2013 on April 9, 2013 3:00 PM-5:00 PM
Phase I Studies of Immune-Based Therapies and a Novel RNAi Agent
A phase I dose escalation study of TKM-080301, a RNAi therapeutic directed against PLK1, in patients with advanced solid tumors
Ramesh K Ramanathan
Virginia G. Piper Cancer Center/TGen, Scottsdale, AZ, United States
from AACR Annual Meeting 2013 on April 9, 2013 3:00 PM-5:00 PM
Phase I Studies of Immune-Based Therapies and a Novel RNAi Agent
Discussant
Josep Tabernero
Vall d'Hebron University Hospital, Barcelona, Spain
from AACR Annual Meeting 2013 on April 9, 2013 3:00 PM-5:00 PM
Phase I Studies of Immune-Based Therapies and a Novel RNAi Agent
Targeting MUC16 with the antibody-drug conjugate (ADC) DMUC5754A in patients with platinum-resistant ovarian cancer: A phase I study of safety and pharmacokinetics
Joyce Liu
Harvard Medical School, Boston, MA, United States
from AACR Annual Meeting 2013 on April 9, 2013 3:00 PM-5:00 PM
Phase I Studies of Immune-Based Therapies and a Novel RNAi Agent
First-in-human phase I dose escalation study of a novel anti-mesothelin antibody drug conjugate (ADC), BAY 94-9343, in patients with advanced solid tumors
Johanna Bendell
Sarah Cannon Research Institute, Nashville, TN, United States
from AACR Annual Meeting 2013 on April 9, 2013 3:00 PM-5:00 PM
Phase I Studies of Immune-Based Therapies and a Novel RNAi Agent
Discussant
Mitchell Ho
National Cancer Inst., Bethesda, MD, United States
from AACR Annual Meeting 2013 on April 9, 2013 3:00 PM-5:00 PM
<< first | < prev page: of 1 records per page: next > | last >>
pages: 1 presentations: 1 to 7 of 7